Scientists discover a natural compound in pomegranate leaves that can break harmful transthyretin amyloid clumps linked to ATTR disease.

Hereditary ATTR-CM can run in families. Learn who may be at risk, when genetic testing is recommended, the benefits of screening, and how to talk with relatives.

In fact, among Medicare beneficiaries aged 65 years or older, the incidence of transthyretin cardiac amyloidosis (ATTR-CM) diagnoses rose from about 10.1 per 100,000 person-years ...

In this opening episode titled, ‘Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Clinical Burden and Diagnostic Challenges,’ moderator, Dr. Ryan Haumschild, and panelist, Dr. Kevin Alexander, ...

Cathie Wood, the CEO of the investment management firm Ark Invest, is known for focusing on companies with significant ...

Researchers identified PGG, a pomegranate compound, as an amyloid disruptor that breaks down toxic transthyretin aggregates.

Researchers have identified a natural compound from pomegranate leaves and branches that can directly dismantle the protein aggregates responsible for transthyretin amyloidosis.

US FDA lifts clinical hold of Intellia Therapeutics’ MAGNITUDE phase 3 trial of nex-z for patients with transthyretin amyloidosis with cardiomyopathy: Cambridge, Massachusetts W ...

A research team at Kumamoto University has discovered that a natural compound found in pomegranate leaves and branches can directly break down harmful protein aggregates linked to transthyretin (TTR) ...

Intellia said the FDA removed the clinical hold on application for the Phase 3 clinical trial of nexiguran ziclumeran. The study is a randomized, double-blind, placebo-controlled trial evaluating the ...

Networked models of care have the potential to provide better access to specialist care for rare diseases in the NHS. The government committed to establishing an innovative networked model of care for ...

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine ...